123Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Czechia
Neuroscience Intelligence
Czechia neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #25 of 50 · Data maturity A · Research score 36.1 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
31Recruiting trials
37Publications
39Institutions
Executive interpretation
Czechia ranks #25 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC97 recruiting
UCB Pharma60 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.60 recruiting
Boehringer Ingelheim50 recruiting
Masaryk University51 recruiting
Ipsen42 recruiting
Eisai Limited30 recruiting
Biogen31 recruiting
Genzyme, a Sanofi Company30 recruiting
Amgen21 recruiting
Disease activity
Parkinsons23trials
Epilepsy22trials
Multiple Sclerosis14trials
Alzheimers14trials
Other Neurology10trials
Pain Neuropathy6trials
Stroke5trials
Migraine Headache5trials
Schizophrenia4trials
Depression3trials
Research institutions
Na Homolce HospitalOpenAlexlinked institution
Czech Academy of Sciences, Institute of BotanyOpenAlexlinked institution
Czech Academy of SciencesOpenAlexlinked institution
Czech Society for OrnithologyOpenAlexlinked institution
Czech Academy of Sciences, Institute of MicrobiologyOpenAlexlinked institution
University of South Bohemia in České BudějoviceOpenAlexlinked institution
St. Anne's University Hospital BrnoOpenAlexlinked institution
University Hospital Hradec KrálovéOpenAlexlinked institution
Zdravotní Ústav Se Sídlem v Ústí nad LabemOpenAlexlinked institution
Masaryk Memorial Cancer InstituteOpenAlexlinked institution
Clinical evidence trail
NCT07798674TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic AtaxiasRECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07067463A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRECRUITING
NCT07018713A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigraineRECRUITING
NCT06976216A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseRECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRECRUITING
Research evidence trail
PUBMED4-Methylumbelliferone Restores Age-Related Changes in Perineuronal Nets, Memory, and Neuroinflammation.2026-12-01
PUBMEDCerebrospinal fluid and serum cytokine and CXCL13 profiles in clinically isolated syndrome.2026-11-01
PUBMEDDepression in people with epilepsy: reliability and validity of the Czech version of Beck Depression Inventory (BDI-II) and Beck Depression Fast Screen (BDI-FS) for major depressive episode.2026-11-01
PUBMEDCaregiver burden and care context in families with Dravet syndrome - a nationwide study in the Czech Republic.2026-11-01
PUBMEDWhen tau goes electric: The first report of a positive correlation between tau burden and ex vivo hyperexcitability in human epileptic hippocampal slices.2026-11-01
PUBMEDCathodal transcranial direct current stimulation in pediatric epileptic syndromes: mechanisms, limitations, and future research horizons.2026-10-12
PUBMEDTranscriptomic analysis reveals distinct expression patterns in focal cortical dysplasia.2026-10-12
PUBMEDDe novo progressive multifocal leukoencephalopathy during ocrelizumab treatment in a patient with primary progressive multiple sclerosis.2026-09-30
PUBMEDScreening speech disorders in progressive neurological diseases via long-term average spectrum.2026-09-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.